Understanding/VBG
Epistatic/JJ
Interactions/NNS
between/IN
Genes/NNS
Targeted/VBN
by/IN
Non-coding/JJ
Regulatory/JJ
Elements/NNS
in/IN
Complex/NN
Diseases/NNS
./.
====================
Genome-wide/NN
association/NN
studies/NNS
have/VBP
proven/VBN
the/DT
highly/RB
polygenic/JJ
architecture/NN
of/IN
complex/NN
diseases/NNS
or/CC
traits/VBZ
;/:
therefore/RB
,/,
single-locus-based/VBN
methods/NNS
are/VBP
usually/RB
unable/JJ
to/TO
detect/VB
all/DT
involved/VBN
loci/NNS
,/,
especially/RB
when/WRB
individual/JJ
loci/NNS
exert/VBP
small/JJ
effects/NNS
./.
====================
Moreover/RB
,/,
the/DT
majority/NN
of/IN
associated/VBN
single-nucleotide/JJ
polymorphisms/NNS
resides/VBZ
in/IN
non-coding/JJ
regions/NNS
,/,
making/VBG
it/PRP
difficult/JJ
to/TO
understand/VB
their/PRP$
phenotypic/JJ
contribution/NN
./.
====================
In/IN
this/DT
work/NN
,/,
we/PRP
studied/VBD
epistatic/JJ
interactions/NNS
associated/VBN
with/IN
three/CD
common/JJ
diseases/NNS
using/VBG
Korea/NN
Association/NN
Resource/NN
(/(
KARE/NN
)/)
data/NNS
:/:
type/NN
2/CD
diabetes/NNS
mellitus/NN
(/(
DM/NN
)/)
,/,
hypertension/NN
(/(
HT/NN
)/)
,/,
and/CC
coronary/JJ
artery/NN
disease/NN
(/(
CAD/NN
)/)
./.
====================
We/PRP
showed/VBD
that/IN
epistatic/JJ
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
were/VBD
enriched/VBN
in/IN
enhancers/NNS
,/,
as/IN
well/RB
as/IN
in/IN
DNase/NN
I/CD
footprints/NNS
(/(
the/DT
Encyclopedia/NN
of/IN
DNA/NN
Elements/NNS
[/(
ENCODE/NNP
]/)
Project/JJ
Consortium/NN
2012/CD
)/)
,/,
which/WDT
suggested/VBD
that/IN
the/DT
disruption/NN
of/IN
the/DT
regulatory/JJ
regions/NNS
where/WRB
transcription/NN
factors/NNS
bind/VBP
may/MD
be/VB
involved/VBN
in/IN
the/DT
disease/NN
mechanism/NN
./.
====================
Accordingly/RB
,/,
to/TO
identify/VB
the/DT
genes/NNS
affected/VBN
by/IN
the/DT
SNPs/NNS
,/,
we/PRP
employed/VBD
whole-genome/WP$
multiple-cell-type/JJ
enhancer/NN
data/NNS
which/WDT
discovered/VBD
using/VBG
DNase/NN
I/CD
profiles/NNS
and/CC
Cap/NN
Analysis/NN
Gene/NN
Expression/NN
(/(
CAGE/NN
)/)
./.
====================
Assigned/VBN
genes/NNS
were/VBD
significantly/RB
enriched/JJ
in/IN
known/VBN
disease/NN
associated/VBN
gene/NN
sets/NNS
,/,
which/WDT
were/VBD
explored/VBN
based/VBN
on/IN
the/DT
literature/NN
,/,
suggesting/VBG
that/IN
this/DT
approach/NN
is/VBZ
useful/JJ
for/IN
detecting/VBG
relevant/JJ
affected/VBN
genes/NNS
./.
====================
In/IN
our/PRP$
knowledge-based/VBN
epistatic/JJ
network/NN
,/,
the/DT
three/CD
diseases/NNS
share/VBP
many/JJ
associated/VBN
genes/NNS
and/CC
are/VBP
also/RB
closely/RB
related/JJ
with/IN
each/DT
other/JJ
through/IN
many/JJ
epistatic/JJ
interactions/NNS
./.
====================
These/DT
findings/NNS
elucidate/VBP
the/DT
genetic/JJ
basis/NN
of/IN
the/DT
close/JJ
relationship/NN
between/IN
DM/NN
,/,
HT/NN
,/,
and/CC
CAD/NN
./.
====================
Recent/JJ
data/NNS
have/VBP
shown/VBN
the/DT
inextricable/JJ
relationship/NN
between/IN
diabetes/NNS
mellitus/NN
(/(
DM/NN
)/)
,/,
hypertension/NN
(/(
HT/NN
)/)
,/,
and/CC
coronary/JJ
artery/NN
disease/NN
(/(
CAD/NN
)/)
./.
====================
For/IN
instance/NN
,/,
approximately/RB
70/CD
%/NN
of/IN
patients/NNS
with/IN
DM/NN
reported/VBD
being/VBG
affected/VBN
by/IN
HT/NN
,/,
which/WDT
is/VBZ
about/RB
twice/RB
as/IN
common/JJ
in/IN
patients/NNS
with/IN
DM/NN
as/IN
in/IN
those/DT
without/IN
it/PRP
[/(
1/CD
]/)
./.
====================
Furthermore/RB
,/,
patients/NNS
with/IN
both/DT
DM/NN
and/CC
HT/NN
were/VBD
reported/VBN
to/TO
have/VB
double/JJ
the/DT
risk/NN
for/IN
CAD/NN
,/,
which/WDT
is/VBZ
the/DT
most/JJS
prevalent/JJ
cause/VBP
of/IN
morbidity/NN
in/IN
type/NN
1/CD
or/CC
type/NN
2/CD
DM/NN
[/(
2/CD
]/)
./.
====================
However/RB
,/,
the/DT
underlying/VBG
genetic/JJ
contributions/NNS
driving/VBG
the/DT
increased/VBN
prevalence/NN
of/IN
HT/NN
and/CC
CAD/NN
in/IN
diabetic/JJ
patients/NNS
are/VBP
poorly/RB
understood/VBN
./.
====================
There/EX
have/VBP
been/VBN
many/JJ
studies/NNS
seeking/VBG
to/TO
understand/VB
the/DT
mechanisms/NNS
of/IN
complex/NN
traits/VBZ
using/VBG
a/DT
single-locus-based/JJ
approach/NN
,/,
but/CC
they/PRP
have/VBP
not/RB
been/VBN
capable/JJ
of/IN
explaining/VBG
their/PRP$
complicated/VBN
genetic/JJ
effects/NNS
./.
====================
Instead/RB
,/,
it/PRP
is/VBZ
necessary/JJ
to/TO
consider/VB
the/DT
joint/NN
genetic/JJ
effects/NNS
produced/VBD
through/IN
the/DT
simultaneous/JJ
perturbation/NN
of/IN
epistatically/RB
interacting/VBG
variants/NNS
./.
====================
Consequently/RB
,/,
epistasis/NN
is/VBZ
now/RB
increasingly/RB
assumed/VBN
to/TO
be/VB
an/DT
important/JJ
factor/NN
in/IN
demonstrating/VBG
complex/NN
disease/NN
,/,
and/CC
there/EX
are/VBP
many/JJ
studies/NNS
in/IN
which/WDT
evidence/NN
of/IN
epistasis/NN
has/VBZ
been/VBN
found/VBN
[/(
3/CD
]/)
./.
====================
Unfortunately/RB
,/,
in/IN
spite/NN
of/IN
such/JJ
efforts/NNS
,/,
most/JJS
such/JJ
studies/NNS
usually/RB
have/VBP
been/VBN
conducted/VBN
in/IN
a/DT
European/JJ
descent/JJ
cohort/NN
[/(
4/CD
]/)
and/CC
have/VBP
not/RB
included/VBN
any/DT
Asian/JJ
patients/NNS
./.
====================
In/IN
this/DT
work/NN
,/,
we/PRP
performed/VBD
a/DT
genomewide/NN
epistasis/NN
analysis/NN
using/VBG
the/DT
East/JJ
Asian/JJ
cohort/NN
from/IN
Korea/NN
Association/NN
Resource/NN
(/(
KARE/NN
)/)
data/NNS
./.
====================
This/DT
is/VBZ
meaningful/JJ
work/NN
,/,
because/IN
obvious/JJ
differences/NNS
exist/VBP
between/IN
ethnically/RB
diverse/JJ
populations/NNS
,/,
such/JJ
as/IN
susceptibility/NN
genes/NNS
,/,
allele/NN
frequency/NN
,/,
and/CC
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
structure/NN
./.
====================
Most/JJS
genetic/JJ
variants/NNS
associated/VBN
with/IN
complex/NN
disease/NN
are/VBP
usually/RB
located/JJ
in/IN
non-coding/JJ
genomic/JJ
regions/NNS
,/,
and/CC
many/JJ
studies/NNS
have/VBP
suggested/VBN
that/IN
such/JJ
variants/NNS
might/MD
be/VB
involved/VBN
in/IN
a/DT
transcriptional/JJ
regulatory/JJ
role/NN
[/(
5/CD
]/)
./.
====================
In/IN
this/DT
regard/NN
,/,
when/WRB
building/VBG
an/DT
appropriate/JJ
model/NN
,/,
it/PRP
can/MD
be/VB
very/RB
limiting/VBG
to/TO
assign/VB
affected/VBN
genes/NNS
using/VBG
only/RB
the/DT
nearest/JJ
ones/NNS
./.
====================
For/IN
systematic/JJ
annotation/NN
,/,
therefore/RB
,/,
we/PRP
have/VBP
suggested/VBN
extensive/JJ
non-coding/JJ
variant/JJ
annotation/NN
using/VBG
regulatory/JJ
elements/NNS
,/,
including/VBG
promoters/NNS
and/CC
distal/JJ
enhancers/NNS
./.
====================
In/IN
this/DT
work/NN
,/,
we/PRP
illustrate/VBP
how/WRB
this/DT
annotation/NN
method/NN
can/MD
be/VB
used/VBN
to/TO
establish/VB
a/DT
reasonable/JJ
genetic/JJ
model/NN
in/IN
complex/NN
diseases/NNS
./.
====================
KARE/NN
data/NNS
====================
We/PRP
used/VBD
352,228/CD
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
genotyped/VBD
using/VBG
Affymetrix/JJ
Genomewide/NN
Human/JJ
SNP/NN
Array/NN
5.0/CD
(/(
genomic/JJ
coordinates/VBZ
hg18/CD
;/:
Affymetrix/JJ
Inc./NNP
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
for/IN
8,842/CD
Korean/JJ
individuals/NNS
from/IN
the/DT
KARE/NN
project/VB
./.
====================
We/PRP
converted/VBD
hg18/NN
to/TO
hg19/NN
using/VBG
the/DT
liftOver/NN
tool/NN
from/IN
UCSC/NN
(/(
http/NN
:/:
//genome.ucsc.edu/cgi-bin/hgLiftOver/RB
)/)
and/CC
converted/VBD
Affymetrix/JJ
ID/NN
to/TO
dbSNP/NN
reference/VBP
cluster/NN
ID/NN
using/VBG
the/DT
annotation/NN
file/JJ
offered/VBD
by/IN
Affymetrix/JJ
(/(
http/NN
:/:
//affymetrix.com/IN
)/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
focused/VBD
on/IN
DM/NN
,/,
HT/NN
,/,
and/CC
CAD/NN
(/(
myocardial/JJ
infarction/NN
and/CC
CAD/NN
)/)
and/CC
considered/VBN
people/NN
who/WP
did/VBD
not/RB
have/VB
any/DT
disease/NN
as/IN
the/DT
controls/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
Epistasis/NN
detection/NN
using/VBG
GPU-based/JJ
Boolean/JJ
Operation-based/JJ
Screening/JJ
and/CC
Testing/JJ
====================
We/PRP
applied/VBD
GPU-based/JJ
Boolean/JJ
Operation-based/JJ
Screening/JJ
and/CC
Testing/JJ
(/(
GBOOST/NN
)/)
to/TO
analyze/VB
epistatic/JJ
interaction/NN
effects/NNS
from/IN
the/DT
genomewide/NN
SNP/NN
data/NNS
[/(
6/CD
]/)
./.
====================
Stage/NN
I/NN
:/:
screening-in/NN
the/DT
screening/NN
stage/NN
,/,
BOOST/NN
evaluated/VBD
all/DT
pairwise/JJ
interactions/NNS
using/VBG
the/DT
Kirkwood/NN
superposition/NN
approximation/NN
./.
====================
Stage/NN
2/CD
:/:
testing-pairs/NNS
of/IN
epistatic/JJ
loci/NNS
with/IN
PBOOST/NN
≤/CD
4.89e-06/CD
were/VBD
further/RB
evaluated/VBD
by/IN
a/DT
logistic/JJ
regression/NN
model/NN
to/TO
compute/VB
interaction/NN
effects/NNS
[/(
7/CD
]/)
./.
====================
After/IN
that/DT
,/,
GBOOST/NN
conducted/VBN
a/DT
χ2/NN
test/NN
with/IN
four/CD
degrees/NNS
of/IN
freedom/JJ
(/(
df/NN
=/JJ
4/CD
)/)
and/CC
calculated/VBN
p-values/NNS
to/TO
determine/VB
whether/IN
the/DT
interaction/NN
effect/NN
was/VBD
significant/JJ
./.
====================
The/DT
numbers/NNS
of/IN
interactions/NNS
tested/VBN
were/VBD
226,507/CD
,/,
251,344/CD
,/,
and/CC
151,090/CD
in/IN
DM/NN
,/,
HT/NN
,/,
and/CC
CAD/NN
,/,
respectively/RB
;/:
thus/RB
,/,
the/DT
genome-wide/NN
significance/NN
levels/NNS
were/VBD
4.41e-08/CD
,/,
3.98e-08/CD
,/,
and/CC
6.62e-08/CD
using/VBG
Bonferroni/NNP
correction/NN
./.
====================
Enrichment/JJ
of/IN
epistatic/JJ
SNPs/NNS
in/IN
regulatory/JJ
elements/NNS
====================
To/TO
test/VB
for/IN
the/DT
enrichment/JJ
of/IN
epistatic/JJ
SNPs/NNS
(/(
Table/JJ
2/CD
)/)
in/IN
regulatory/JJ
elements/NNS
,/,
we/PRP
overlapped/VBD
SNPs/NNS
with/IN
enhancers/NNS
(/(
see/VB
below/IN
)/)
and/CC
footprints/NNS
data/NNS
./.
====================
We/PRP
obtained/VBD
genomic/JJ
DNase/NN
I/CD
footprints/NNS
across/IN
41/CD
cell/NN
types/NNS
from/IN
the/DT
Encyclopedia/NN
of/IN
DNA/NN
Elements/NNS
(/(
ENCODE/NN
)/)
Project/JJ
(/(
The/DT
ENCODE/NN
Project/JJ
Consortium/NN
2012/CD
;/:
http/RB
:/:
//genome.ucsc.edu/ENCODDE/downloads.html/NN
)/)
./.
====================
Nucleotide/JJ
resolution/NN
analysis/NN
of/IN
DNase/NN
I/CD
cleavage/NN
patterns/NNS
allowed/VBD
us/PRP
to/TO
discover/JJ
the/DT
footprints/NNS
of/IN
where/WRB
the/DT
transcription/NN
factor/NN
bound/VBD
[/(
8/CD
]/)
./.
====================
To/TO
determine/VB
whether/IN
the/DT
observed/VBN
count/NN
was/VBD
significantly/RB
greater/JJR
than/IN
expected/VBN
by/IN
chance/NN
,/,
we/PRP
randomly/RB
selected/VBN
7,967/CD
variants/NNS
(/(
the/DT
same/JJ
number/NN
of/IN
epistatic/JJ
SNPs/NNS
)/)
from/IN
dbSNPs/NNS
(/(
59,180,134/CD
autosomal/JJ
SNPs/NNS
)/)
and/CC
repeated/VBN
the/DT
overlap/JJ
analysis/NN
1,000/CD
times/NNS
./.
====================
The/DT
level/NN
of/IN
significance/NN
(/(
p-value/NN
)/)
was/VBD
computed/VBN
as/IN
the/DT
proportion/NN
of/IN
counts/NNS
that/DT
were/VBD
equal/JJ
to/TO
or/CC
larger/JJR
than/IN
the/DT
observed/VBN
count/NN
from/IN
the/DT
null/JJ
distribution/NN
./.
====================
Target/NN
gene/NN
mapping/NN
to/TO
SNPs/NNS
using/VBG
regulatory/JJ
elements/NNS
====================
We/PRP
used/VBD
all/DT
transcript/NN
annotations/NNS
from/IN
GENCODE.v19/NN
,/,
which/WDT
contains/VBZ
20,242/CD
protein-coding/VBG
genes/NNS
./.
====================
The/DT
promoter/NN
was/VBD
defined/VBN
as/IN
the/DT
region/NN
1.5/CD
kb/NN
upstream/RB
of/IN
the/DT
transcription/NN
start/NN
site/NN
of/IN
a/DT
gene/NN
./.
====================
When/WRB
a/DT
SNP/NN
was/VBD
in/IN
the/DT
promoter/NN
region/NN
of/IN
a/DT
gene/NN
,/,
we/PRP
assigned/VBD
the/DT
gene/NN
to/TO
the/DT
SNP/NN
./.
====================
In/IN
the/DT
case/NN
of/IN
SNPs/NNS
that/DT
were/VBD
not/RB
assigned/VBN
using/VBG
the/DT
promoter/NN
,/,
we/PRP
assigned/VBD
genes/NNS
using/VBG
the/DT
enhancer/NN
that/IN
was/VBD
connected/VBN
with/IN
the/DT
promoter/NN
of/IN
the/DT
target/NN
gene/NN
./.
====================
We/PRP
obtained/VBD
genomewide/NN
multiple-cell-type/JJ
enhancer/NN
data/NNS
from/IN
previous/JJ
studies/NNS
[/(
9/CD
,/,
10/CD
]/)
./.
====================
Maurano/NN
et/FW
al/JJ
./.
====================
[/(
9/CD
]/)
identified/VBD
distal/JJ
enhancer-to-promoter/NN
connections/NNS
using/VBG
DNase/NN
I/CD
profiles/NNS
across/IN
349/CD
diverse/JJ
cell/NN
types/NNS
,/,
and/CC
Andersson/NN
et/FW
al/JJ
./.
====================
[/(
10/CD
]/)
identified/VBD
extensive/JJ
active/JJ
enhancers/NNS
and/CC
their/PRP$
target/NN
promoters/NNS
by/IN
using/VBG
Cap/NN
Analysis/NN
Gene/NN
Expression/NN
(/(
CAGE/NN
)/)
data/NNS
based/VBN
on/IN
the/DT
FANTOM5/NN
panel/NN
of/IN
~400/CD
distinct/JJ
cell/NN
types/NNS
./.
====================
We/PRP
collected/VBD
a/DT
total/JJ
of/IN
663,583/CD
pairs/NNS
of/IN
enhancers/NNS
and/CC
target/NN
genes/NNS
./.
====================
If/IN
an/DT
SNP/NN
was/VBD
not/RB
assigned/VBN
,/,
we/PRP
looked/VBD
for/IN
the/DT
closest/JJS
SNP/NN
in/IN
LD/NN
based/VBN
on/IN
CHB/JPT/NN
populations/NNS
(/(
Han/NNP
Chinese/JJ
in/IN
Beijing/VBG
,/,
China/Japanese/JJ
in/IN
Tokyo/JJ
,/,
Japan/NNP
;/:
Asian/JJ
ancestry/NN
)/)
with/IN
an/DT
r2/NN
>/JJR
0.8/CD
that/DT
was/VBD
within/IN
500/CD
kb/NN
using/VBG
the/DT
SNAP/NN
proxy/JJ
tool/NN
(/(
http/NN
:/:
//www.broadinstitute.org/mpg/snap//JJ
)/)
[/(
11/CD
]/)
./.
====================
The/DT
summary/NN
of/IN
the/DT
number/NN
of/IN
assigned/VBN
genes/NNS
is/VBZ
shown/VBN
in/IN
Table/JJ
3/CD
./.
====================
Enrichment/JJ
of/IN
the/DT
affected/VBN
genes/NNS
in/IN
the/DT
known/JJ
gene/NN
set/NN
====================
We/PRP
downloaded/VBD
DM-/NN
,/,
HT-/NN
,/,
and/CC
CAD-related/JJ
gene/NN
information/NN
from/IN
Phenopedia/NN
(/(
HuGE/NNP
Navigator/NN
,/,
version/NN
2.0/CD
)/)
[/(
12/CD
]/)
./.
====================
The/DT
HuGE/JJ
Navigator/NN
is/VBZ
an/DT
integrated/JJ
knowledge-based/VBN
database/NN
of/IN
genetic/JJ
associations/NNS
that/IN
have/VBP
been/VBN
extensively/RB
explored/VBN
,/,
based/VBN
on/IN
the/DT
literature/NN
,/,
and/CC
is/VBZ
continuously/RB
updated/VBN
from/IN
PubMed/JJ
(/(
http/NN
:/:
//www.ncbi.nlm.nih.gov/pubmed//JJ
)/)
./.
====================
To/TO
test/VB
whether/IN
the/DT
genes/NNS
we/PRP
discovered/VBD
were/VBD
statistically/RB
enriched/JJ
within/IN
known/VBN
genes/NNS
involving/VBG
the/DT
disease/NN
,/,
we/PRP
calculated/VBD
the/DT
p-value/JJ
using/VBG
the/DT
hyper-geometric/JJ
test/NN
:/:
where/WRB
N/NN
represents/VBZ
the/DT
total/JJ
number/NN
of/IN
genes/NNS
(/(
N/NN
=/JJ
20,242/CD
)/)
,/,
n/NN
is/VBZ
the/DT
number/NN
of/IN
genes/NNS
we/PRP
found/VBD
,/,
and/CC
M/NN
and/CC
k/JJ
are/VBP
the/DT
number/NN
of/IN
genes/NNS
in/IN
the/DT
known/JJ
DB/NN
(/(
Table/JJ
3/CD
)/)
and/CC
that/IN
overlap/IN
,/,
respectively/RB
./.
====================
In/IN
the/DT
KARE/NN
dataset/NN
,/,
there/EX
were/VBD
substantial/JJ
overlaps/VBZ
between/IN
the/DT
cases/NNS
of/IN
DM/NN
,/,
HT/NN
,/,
and/CC
CAD/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
We/PRP
found/VBD
that/IN
the/DT
occurrence/NN
of/IN
one/CD
disease/NN
was/VBD
largely/RB
dependent/JJ
on/IN
another/DT
./.
====================
For/IN
example/NN
,/,
the/DT
incidence/NN
of/IN
HT/NN
was/VBD
significantly/RB
associated/VBN
with/IN
CAD/NN
(/(
odds/NNS
ratio/NN
,/,
2.39/CD
;/:
95/CD
%/NN
confidence/NN
interval/JJ
[/(
CI/NN
]/)
,/,
1.64/CD
to/TO
3.48/CD
;/:
p/NN
=/JJ
4.29e-06/CD
)/)
./.
====================
Similarly/RB
,/,
the/DT
odds/NNS
ratio/NN
of/IN
incident/JJ
DM/NN
for/IN
HT/NN
versus/CC
normal/JJ
was/VBD
2.15/CD
(/(
95/CD
%/NN
CI/NN
,/,
1.79/CD
to/TO
2.56/CD
;/:
p/NN
=/JJ
2.20e-16/CD
)/)
,/,
and/CC
the/DT
odds/NNS
ratio/NN
of/IN
CAD/NN
for/IN
DM/NN
was/VBD
1.68/CD
(/(
95/CD
%/NN
CI/NN
,/,
1.02/CD
to/TO
2.68/CD
;/:
p/NN
=/JJ
2.82e-02/CD
)/)
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
We/PRP
analyzed/VBD
all/DT
pairwise/JJ
interaction/NN
effects/NNS
from/IN
the/DT
KARE/NN
data/NNS
using/VBG
GBOOST/NN
./.
====================
As/IN
the/DT
result/NN
,/,
we/PRP
detected/VBD
1,962/CD
,/,
2,023/CD
,/,
and/CC
1,709/CD
epistatic/JJ
interactions/NNS
in/IN
DM/NN
,/,
HT/NN
,/,
and/CC
CAD/NN
,/,
respectively/RB
(/(
Table/JJ
3/CD
)/)
./.
====================
For/IN
a/DT
full/JJ
list/NN
,/,
see/VB
the/DT
Supplementary/JJ
Tables/NNS
1,2,3/NN
./.
====================
We/PRP
overlapped/VBD
these/DT
epistatic/JJ
SNPs/NNS
within/IN
genomic/JJ
regions/NNS
,/,
including/VBG
the/DT
promoter/NN
,/,
gene/NN
distal/JJ
region/NN
,/,
intron/NN
,/,
and/CC
exon/NN
./.
====================
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
As/IN
a/DT
result/NN
,/,
the/DT
majority/NN
of/IN
detected/VBN
epistatic/JJ
SNPs/NNS
was/VBD
found/VBN
to/TO
reside/VB
in/IN
non-coding/JJ
regions/NNS
,/,
especially/RB
within/IN
introns/NNS
and/CC
gene/NN
distal/JJ
regions/NNS
,/,
which/WDT
are/VBP
intergenic/JJ
regions/NNS
,/,
excluding/VBG
promoters/NNS
./.
====================
Furthermore/RB
,/,
we/PRP
tested/VBD
whether/IN
the/DT
epistatic/JJ
SNPs/NNS
were/VBD
enriched/VBN
in/IN
regulatory/JJ
element/NN
,/,
such/JJ
as/IN
enhancers/NNS
and/CC
DNase/NN
I/CD
footprints/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
We/PRP
identified/VBD
statistically/RB
significant/JJ
enrichment/JJ
of/IN
the/DT
SNPs/NNS
in/IN
enhancer/NN
regions/NNS
(/(
p/NN
=/JJ
0.001/CD
)/)
,/,
as/IN
well/RB
as/IN
DNase/NN
I/CD
footprint/NN
regions/NNS
(/(
p/NN
</JJR
0.001/CD
)/)
./.
====================
This/DT
suggests/VBZ
that/IN
the/DT
disruption/NN
of/IN
regulatory/JJ
factor/NN
binding/NN
might/MD
be/VB
involved/VBN
in/IN
the/DT
disease/NN
mechanism/NN
./.
====================
For/IN
that/DT
reason/NN
,/,
we/PRP
annotated/VBD
epistatic/JJ
SNPs/NNS
using/VBG
regulatory/JJ
element/NN
information/NN
,/,
including/VBG
promoters/NNS
,/,
as/IN
well/RB
as/IN
enhancers/NNS
(/(
see/VB
Methods/NNS
)/)
./.
====================
We/PRP
also/RB
proved/VBD
that/IN
the/DT
assigned/VBN
genes/NNS
were/VBD
enriched/VBN
in/IN
each/DT
known/VBN
disease-associated/JJ
gene/NN
set/NN
(/(
Table/JJ
3/CD
)/)
./.
====================
We/PRP
built/VBP
a/DT
knowledge-based/JJ
epistatic/JJ
network/NN
./.
====================
We/PRP
discovered/VBD
that/DT
the/DT
diseases/NNS
share/VBP
many/JJ
associated/VBN
genes/NNS
and/CC
also/RB
have/VBP
a/DT
number/NN
of/IN
epistatic/JJ
interactions/NNS
within/IN
and/CC
between/IN
genes/NNS
involved/VBN
in/IN
each/DT
disease/NN
(/(
Fig/NN
./.
====================
4/CD
)/)
./.
====================
For/IN
a/DT
detailed/JJ
list/NN
,/,
see/VB
the/DT
Supplementary/JJ
Table/JJ
4/CD
./.
====================
For/IN
example/NN
,/,
we/PRP
detected/VBD
an/DT
epistatic/JJ
interaction/NN
effect/NN
between/IN
atypical/JJ
protein/NN
kinase/NN
C/NN
isotype-specific/JJ
interacting/VBG
protein/NN
(/(
ASIP/NN
)/)
and/CC
hexokinase/NN
II/CD
(/(
HK2/NN
)/)
in/IN
DM/NN
./.
====================
Previous/JJ
studies/NNS
have/VBP
reported/VBN
that/IN
overexpression/NN
of/IN
ASIP/NN
inhibits/VBZ
insulin-induced/JJ
glucose/NN
uptake/NN
[/(
13/CD
]/)
,/,
and/CC
HK2/NN
plays/VBZ
a/DT
central/JJ
role/NN
in/IN
glucose/NN
metabolism/NN
[/(
14/CD
]/)
./.
====================
Our/PRP$
result/NN
implies/VBZ
that/IN
gene/NN
pairs/NNS
,/,
such/JJ
as/IN
ASIP/NN
and/CC
HK2/NN
,/,
could/MD
boost/VB
the/DT
incidence/NN
of/IN
DM/NN
through/IN
epistatic/JJ
interactions/NNS
./.
====================
We/PRP
also/RB
detected/VBN
several/JJ
significant/JJ
epistatic/JJ
interaction/NN
effects/NNS
in/IN
CAD/NN
and/CC
HT/NN
between/IN
several/JJ
DM-associated/JJ
gene/NN
pairs/NNS
./.
====================
This/DT
finding/NN
could/MD
provide/VB
a/DT
genetic/JJ
basis/NN
for/IN
the/DT
increased/VBN
prevalence/NN
of/IN
CAD/NN
and/CC
HT/NN
in/IN
diabetic/JJ
patients/NNS
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
carried/VBD
out/RP
a/DT
genomewide/JJ
epistasis/NN
analysis/NN
to/TO
understand/VB
the/DT
comprehensive/JJ
genetic/JJ
relationships/NNS
between/IN
DM/NN
,/,
HT/NN
,/,
and/CC
CAD/NN
in/IN
a/DT
Korean/JJ
cohort/NN
./.
====================
For/IN
systematic/JJ
annotation/NN
,/,
we/PRP
employed/VBD
whole-genome/WP$
multiple-cell-type/JJ
enhancer/NN
data/NNS
,/,
because/IN
the/DT
majority/NN
of/IN
detected/VBN
epistatic/JJ
SNPs/NNS
was/VBD
located/JJ
in/IN
non-coding/JJ
regions/NNS
./.
====================
Our/PRP$
enrichment/JJ
analysis/NN
in/IN
regulatory/JJ
DNA/NN
regions/NNS
identified/VBD
substantial/JJ
variants/NNS
that/WDT
might/MD
affect/VB
transcriptional/JJ
regulatory/JJ
function/NN
through/IN
disruptions/NNS
of/IN
promoter/NN
or/CC
enhancer/NN
elements/NNS
where/WRB
regulatory/JJ
factors/NNS
bind/VBP
./.
====================
We/PRP
confirmed/VBD
that/IN
the/DT
genes/NNS
that/WDT
were/VBD
discovered/VBN
using/VBG
the/DT
non-coding/JJ
element/NN
are/VBP
statistically/RB
enriched/JJ
in/IN
known/VBN
genes/NNS
involved/VBN
in/IN
the/DT
diseases/NNS
,/,
which/WDT
suggests/VBZ
that/IN
this/DT
annotation/NN
method/NN
is/VBZ
considerably/RB
relevant/JJ
./.
====================
We/PRP
found/VBD
that/IN
the/DT
diseases/NNS
shared/VBN
many/JJ
associated/VBN
genes/NNS
,/,
implying/VBG
their/PRP$
inseparable/JJ
relationship/NN
./.
====================
A/DT
large/JJ
number/NN
of/IN
epistatic/JJ
interactions/NNS
were/VBD
also/RB
intricately/RB
connected/VBD
between/IN
genes/NNS
involved/VBN
in/IN
DM/NN
,/,
HT/NN
,/,
and/CC
CAD/NN
./.
====================
This/DT
integrated/JJ
map/VBP
,/,
based/VBN
on/IN
epistatic/JJ
interactions/NNS
,/,
could/MD
provide/VB
a/DT
genetic/JJ
basis/NN
for/IN
the/DT
underlying/VBG
mechanisms/NNS
of/IN
the/DT
increased/VBN
prevalence/NN
of/IN
the/DT
diseases/NNS
'/``
dependence/NN
on/IN
one/CD
another/DT
./.
====================
In/IN
conclusion/NN
,/,
our/PRP$
results/NNS
illustrate/VBP
how/WRB
extensive/JJ
non-coding/JJ
variant/JJ
annotation/NN
based/VBN
on/IN
chromatin/NN
interactions/NNS
of/IN
distal/JJ
enhancers/NNS
can/MD
be/VB
used/VBN
to/TO
dissect/VB
complex/NN
genetic/JJ
interactions/NNS
in/IN
complex/NN
diseases/NNS
./.
====================
The/DT
summary/NN
of/IN
the/DT
incidence/NN
of/IN
diabetes/NNS
mellitus/NN
(/(
DM/NN
)/)
,/,
hypertension/NN
(/(
HT/NN
)/)
,/,
and/CC
coronary/JJ
artery/NN
disease/NN
(/(
CAD/NN
)/)
./.
====================
(/(
A/NN
)/)
Venn/NNP
diagram/NN
illustrating/VBG
the/DT
overlaps/VBZ
among/IN
diseases/NNS
./.
====================
(/(
B/NN
)/)
The/DT
odds/NNS
ratio/NN
(/(
OR/NN
)/)
for/IN
the/DT
disease/NN
incidence/NN
./.
====================
Pie/NN
chart/NN
representing/VBG
the/DT
genomic/JJ
regions/NNS
of/IN
epistatic/JJ
single/JJ
nucleotide/NN
polymorphisms/NNS
./.
====================
CAD/NN
,/,
coronary/JJ
artery/NN
disease/NN
;/:
DM/NN
,/,
diabetes/VBZ
mellitus/NN
;/:
HT/NN
,/,
hypertension/NN
./.
====================
Enrichment/JJ
of/IN
epistatic/JJ
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
in/IN
enhancer/NN
and/CC
DNase/NN
I/CD
footprints/NNS
./.
====================
The/DT
distribution/NN
of/IN
expected/VBN
overlaps/VBZ
was/VBD
obtained/VBN
from/IN
1,000/CD
random/JJ
sets/NNS
./.
====================
A/DT
red/JJ
line/NN
indicates/VBZ
the/DT
observed/VBN
count/NN
of/IN
SNPs/NNS
in/IN
enhancer/NN
and/CC
DNase/NN
I/CD
footprints/NNS
./.
====================
The/DT
knowledge-based/VBN
epistatic/JJ
network/NN
between/IN
coronary/JJ
artery/NN
disease/NN
(/(
CAD/NN
)/)
,/,
diabetes/VBZ
mellitus/NN
(/(
DM/NN
)/)
,/,
and/CC
hypertension/NN
(/(
HT/NN
)/)
./.
====================
Uncolored/JJ
circles/NNS
connected/VBN
by/IN
gray/JJ
lines/NNS
with/IN
colored/JJ
circles/NNS
indicate/VBP
genes/NNS
known/VBN
to/TO
be/VB
involved/VBN
with/IN
DM/NN
(/(
green/CD
)/)
,/,
HT/NN
(/(
blue/JJ
)/)
and/CC
CAD/NN
(/(
red/JJ
)/)
,/,
respectively/RB
./.
====================
The/DT
colored/JJ
lines/NNS
indicate/VBP
the/DT
epistatic/JJ
interactions/NNS
detected/VBN
in/IN
DM/NN
(/(
green/CD
)/)
,/,
HT/NN
(/(
blue/JJ
)/)
and/CC
CAD/NN
(/(
red/JJ
)/)
patients/NNS
./.
====================
Summary/JJ
of/IN
KARE/NN
data/NNS
used/VBN
====================
Summary/JJ
of/IN
detected/VBN
epistatic/JJ
interactions/NNS
====================
Target/NN
gene/NN
assignment/NN
and/CC
enrichment/JJ
analysis/NN
using/VBG
known/VBN
DB/NN
across/IN
diseases/NNS
====================
